Rheumatology Updates: Lobbying Efforts, SGLT2 Inhibitors, and Opioid Use

Recent developments in rheumatology encompass a range of critical areas, from advocacy and policy to emerging therapeutic benefits and responsible medication management. Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights these key topics in a recent interview.

Lobbying Efforts in a Changing Political Landscape

Medical groups are actively engaged in lobbying efforts amid increasing governmental pressures on healthcare, research funding, and resource allocation. These efforts aim to advocate for the needs of patients and healthcare professionals across various rheumatic diseases. The evolving political landscape necessitates proactive engagement to ensure continued progress in research and patient care.

SGLT2 Inhibitors Show Promise in Lupus and Diabetes

Emerging data suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors may offer survival benefits for patients with both lupus and diabetes. Dr. Calabrese notes that SGLT2 inhibitors are demonstrating potent immunomodulating effects, opening modern avenues for therapeutic intervention. Further research is underway to fully understand the mechanisms and potential applications of these drugs in rheumatology.

Opioid Stewardship in Rheumatology

A recent study revealed that approximately 43% of patients aged 65 years or older with rheumatic disease filled at least one opioid prescription in 2021, with 17.9% receiving chronic opioid prescriptions. Healio Rheumatology. This highlights the ongoing need for careful opioid stewardship and responsible prescribing practices within the rheumatology community. Healthcare providers must prioritize patient safety and explore alternative pain management strategies.

Expert Insights

Leonard H. Calabrese, DO, can be reached at calabrl@ccf.org or through rheumatology@healio.com.

Source: Healio Interviews

Disclosures: Dr. Calabrese reports being a medical advisor for OpenEvidence, as well as professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.